What's taking the FTC so long? Roche won't say, but insists it will bag Spark on time — despite third delay
Roche is delaying its buyout of Spark Therapeutics for a third time, giving itself one last chance to complete the deal within the first half …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
